

Ibnsina Pharma becomes Mundipharma's agent in Egypt, targets EGP 120m revenues by end of 2020

Ibnsina Pharma has signed an agreement with Mundipharma to import and distribute its products in Egypt. Mundipharma's product range covers six therapeutic areas including oncology, respiratory disease, ophthalmology, pain, specialty care, and consumer health. Ibnsina expects revenues from the partnership to reach EGP 120 million by the end of 2020.